W K Oh

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Treatment of locally advanced prostate cancer: is chemotherapy the next step?
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 17:3664-75. 1999
  2. ncbi request reprint Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints
    William K Oh
    Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Urol Oncol 21:229-34. 2003
  3. ncbi request reprint The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 109:1090-6. 2007
  4. ncbi request reprint Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 109:477-86. 2007
  5. ncbi request reprint The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 170:S28-32; discussion S33-4. 2003
  6. ncbi request reprint The evolving role of estrogen therapy in prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Clin Prostate Cancer 1:81-9. 2002
  7. ncbi request reprint Development of an integrated prostate cancer research information system
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Genitourin Cancer 5:61-6. 2006
  8. ncbi request reprint Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 67:1235-40. 2006
  9. ncbi request reprint An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 172:S34-7; discussion S37. 2004
  10. ncbi request reprint A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts 02115, USA
    Clin Cancer Res 11:284-9. 2005

Detail Information

Publications81

  1. ncbi request reprint Treatment of locally advanced prostate cancer: is chemotherapy the next step?
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 17:3664-75. 1999
    ..The purpose of this review is to define the current knowledge in managing locally advanced prostate cancer and to propose new treatment approaches based on current knowledge...
  2. ncbi request reprint Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints
    William K Oh
    Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Urol Oncol 21:229-34. 2003
    ..The neoadjuvant surgical model also has promise in assessing the activity of new drugs, because it provides a means to determine molecular effects of specific agents, along with standard pathologic and clinical parameters of efficacy...
  3. ncbi request reprint The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 109:1090-6. 2007
    ..For this observational study, the authors assessed the risk of renal impairment in patients with HRPC who received zoledronic acid from December 1999 to April 2005...
  4. ncbi request reprint Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 109:477-86. 2007
    ..Satraplatin plus prednisone is being investigated in a large Phase III trial as second-line chemotherapy for HRPC. Targeting neuroendocrine cells may provide a new therapeutic approach to HRPC...
  5. ncbi request reprint The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 170:S28-32; discussion S33-4. 2003
    ..The recent literature is reviewed regarding the use of neoadjuvant and adjuvant chemotherapy, and promising new molecular targeted agents in patients with high risk localized prostate cancer...
  6. ncbi request reprint The evolving role of estrogen therapy in prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Clin Prostate Cancer 1:81-9. 2002
    ..Nonetheless, there remain many unanswered questions about the role of estrogen therapy in prostate cancer, including differences between specific drugs, optimal dose, timing, and patient selection. Further research is needed...
  7. ncbi request reprint Development of an integrated prostate cancer research information system
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Genitourin Cancer 5:61-6. 2006
    ..In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care...
  8. ncbi request reprint Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 67:1235-40. 2006
    ..Clinical trials have demonstrated a survival benefit with docetaxel chemotherapy, but limited data exist regarding the activity of second-line chemotherapy...
  9. ncbi request reprint An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 172:S34-7; discussion S37. 2004
    ..As a result, efforts are being made to decrease the risk of recurrence and delay progression to symptomatic hormone refractory disease using chemotherapy prior to, during or after definitive local therapy...
  10. ncbi request reprint A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts 02115, USA
    Clin Cancer Res 11:284-9. 2005
    ..To define the maximal tolerated dose, safety, and efficacy of docetaxel, carboplatin, and estramustine in patients with hormone-refractory prostate cancer (HRPC)...
  11. ncbi request reprint Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy
    William K Oh
    Department of Medical Oncology, Lake Center for Genitourinary Oncology, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Prostate Cancer 4:61-4. 2005
    ..A clinical trial to evaluate this effect has been initiated...
  12. ncbi request reprint Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:2171-9. 2003
    ..This is important as randomized trials using chemotherapy are proposed. The authors used a questionnaire to investigate the attitudes of physicians in the New England area who care for patients with advanced prostate carcinoma...
  13. ncbi request reprint High-risk localized prostate cancer: integrating chemotherapy
    William K Oh
    Dana Farber Cancer Institute Lank Center for Genitourinary Oncology, 44 Binney Street, Boston, MA 02115, USA
    Oncologist 10:18-22. 2005
    ..Another large randomized trial will be evaluating the effect of adjuvant hormonal therapy with or without docetaxel in high-risk men after radical prostatectomy...
  14. ncbi request reprint Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases
    William K Oh
    The Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 94:686-9. 2002
    ..The objective of the current report is to describe the effects of discontinuing PC-SPES treatment in four patients with androgen-independent prostate carcinoma...
  15. ncbi request reprint Secondary hormonal therapies in the treatment of prostate cancer
    William K Oh
    Department of Adult Oncology, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 60:87-92; discussion 93. 2002
    ..In conclusion, secondary hormonal therapies have a significant role in the treatment of patients with androgen-independent prostate cancer. Further research is needed to understand their optimal use...
  16. doi request reprint Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 75:642-7. 2010
    ..LHRH agonists are associated with initial testosterone rises that may cause clinical disease flares in men with metastatic prostate cancer...
  17. ncbi request reprint A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813
    William K Oh
    Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:2592-8. 2003
    ..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma...
  18. ncbi request reprint Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 62:99-104. 2003
    ..Standard androgen deprivation strategies for prostate cancer typically lead to castrate levels of testosterone. One alternative is the use of finasteride and flutamide...
  19. ncbi request reprint Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 28:40-4. 2001
    ..The primary endpoint of the trial is measurement of pathologic complete response rate, for which data are not yet available. Recruitment to the trial is ongoing...
  20. ncbi request reprint Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy
    Timothy J Daskivich
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 70:527-31. 2007
    ..To investigate whether the prostate-specific antigen doubling time (PSADT) and velocity (PSAV) at the emergence of androgen-independent prostate cancer (AIPC) provide independent prognostic information...
  21. pmc Phase II study of sunitinib in men with advanced prostate cancer
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Oncol 20:913-20. 2009
    ..This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC)...
  22. ncbi request reprint Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
    M H Tay
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 15:974-8. 2004
    ..Effective, less toxic therapies are needed. This study examined whether the addition of finasteride to high-dose bicalutamide enhanced disease control, as measured by additional decreases in serum prostate-specific antigen (PSA)...
  23. ncbi request reprint Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Urology 57:122-6. 2001
    ..Additional testing is necessary to identify the active components of PC-SPES and its role in the treatment of patients with androgen-independent prostate cancer...
  24. ncbi request reprint Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Timothy J Daskivich
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 67:1084.e15-7. 2006
    ....
  25. ncbi request reprint Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
    Phillip G Febbo
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston Massachusetts 02115, USA
    Clin Cancer Res 11:5233-40. 2005
    ..To determine the clinical, pathologic, and molecular effects of neoadjuvant docetaxel chemotherapy in high-risk localized prostate cancer...
  26. ncbi request reprint A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
    Robert W Ross
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:521-6. 2008
    ..The authors conducted a phase 2 trial of docetaxel plus carboplatin chemotherapy in this disease setting...
  27. doi request reprint Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
    ..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)...
  28. ncbi request reprint Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Am J Clin Oncol 26:312-6. 2003
    ..Neoadjuvant liposomal doxorubicin demonstrates no apparent activity and significant toxicity. New strategies are needed to improve outcomes in high-risk prostate cancer...
  29. ncbi request reprint Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer
    Daniel J George
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Urology 63:327-32. 2004
    ..To measure the change in plasma vascular endothelial growth factor (VEGF) levels after radical prostatectomy (RP) and to examine the association of pre-RP VEGF levels with known prognostic factors...
  30. ncbi request reprint Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
    M Dror Michaelson
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 107:530-5. 2006
    ..Atrasentan is an investigational agent that inhibits endothelin-1 receptor, resulting in decreased osteoblast activity...
  31. ncbi request reprint Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 22:3705-12. 2004
    ..To evaluate the herbal combination, PC-SPES, and diethylstilbestrol (DES) in patients with androgen independent prostate cancer (AIPC)...
  32. ncbi request reprint Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 105:1392-6. 2010
    ....
  33. ncbi request reprint Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 107:975-81. 2006
    ..To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC...
  34. ncbi request reprint Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase
    Wanling Xie
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 110:2709-15. 2007
    ..In the current study, the authors evaluated the combined effects of PSA and ALK-P on survival...
  35. ncbi request reprint Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer
    M D Galsky
    Department of Medicine, Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY 10029, USA
    Prostate Cancer Prostatic Dis 16:266-70. 2013
    ..Endorectal magnetic resonance imaging at 1.5‚ÄČTesla (1.5T erMRI) response has been utilized as an end point in neoadjuvant trials but has not been correlated with clinical outcomes...
  36. ncbi request reprint Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone
    Oliver Sartor
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Genitourin Cancer 7:E90-2. 2009
    ..We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone...
  37. ncbi request reprint Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Treat Options Oncol 5:349-55. 2004
    ..We review the recent literature regarding the use of neoadjuvant and adjuvant chemotherapy in patients with locally advanced prostate cancer...
  38. doi request reprint Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  39. ncbi request reprint Chemotherapy for high-risk localized prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street D1230, Boston, MA 02115, USA
    BJU Int 97:679-83. 2006
  40. doi request reprint A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1084-9. 2008
    ..To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites..
  41. pmc Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
    M M Regan
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Ann Oncol 21:312-8. 2010
    ..We investigated whether there is a subset of patients with CRPC for whom the efficacy of combination taxane-estramustine-carboplatin (TEC) chemotherapy may be greatest...
  42. ncbi request reprint Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer
    Mark Pomerantz
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    J Urol 177:2146-50. 2007
    ..We tested 2 doses of the conjugated estrogen Premarin(R) in patients with androgen independent prostate cancer to determine the efficacy and safety of this widely available medication...
  43. ncbi request reprint Complementary and alternative therapies in prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 29:575-84. 2002
    ..Subsequent analyses also revealed the presence of diethylstilbestrol (DES) and indomethacin in some lots of PC-SPES. Available data regarding other alternative therapies are reviewed as well...
  44. ncbi request reprint PC-SPES and prostate cancer
    William K Oh
    Department of Adult Oncology, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Urol Clin North Am 29:59-66, viii. 2002
    ..Toxicity is mild, thought there is an approximately 5% risk of thromboembolic events with treatment. Although PC-SPES has apparent estrogenic activity, controversy exists over the exact mechanism of its effects...
  45. ncbi request reprint Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer J 13:125-9. 2007
    ..However, little is known about the efficacy of VRL as second-line chemotherapy in HRPC...
  46. ncbi request reprint Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, and Children s Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 24:2958-9. 2006
  47. ncbi request reprint Selective aromatase inhibition for patients with androgen-independent prostate carcinoma
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 95:1864-8. 2002
    ..The authors conducted a Phase II clinical study of letrozole to determine the safety and efficacy of a potent and selective third-generation aromatase inhibitor in men with androgen-independent prostate carcinoma...
  48. pmc Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  49. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
    ..Vaccination of patients with RCC with allogeneic DC/tumor fusions was feasible, well tolerated, and resulted in immunologic and clinical responses in a subset of patients...
  50. doi request reprint Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ....
  51. ncbi request reprint Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y Yu
    Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Dana 1230, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 5:250-7. 2003
    ..We review the recent literature regarding the use of neoadjuvant hormonal manipulation, chemotherapy, and promising new molecular targeted agents in patients with high-risk localized prostate cancer...
  52. pmc Evaluation of 8q24 and 17q risk loci and prostate cancer mortality
    Kathryn L Penney
    Department of Epidemiology, Harvard School of Public Health, Harvard University, Cambridge, Massachusetts, USA
    Clin Cancer Res 15:3223-30. 2009
    ..We investigated whether the 8q24 and 17q risk variants are associated with clinical variables as well as prostate cancer mortality...
  53. pmc Use of androgen deprivation therapy for metastatic prostate cancer in older men
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1077-83. 2008
    ....
  54. ncbi request reprint Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    BJU Int 105:1247-54. 2010
    ..To assess the effectiveness, safety, and treatment patterns of anti-angiogenic agents in metastatic renal cell carcinoma (mRCC) in tertiary clinical practice settings...
  55. ncbi request reprint A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Invest 20:186-91. 2002
    ..We conclude that the combination of interferon-alpha plus toremifene demonstrates no significant activity in advanced renal cell carcinoma...
  56. ncbi request reprint Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 101:1569-74. 2004
    ....
  57. doi request reprint Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
    ..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases...
  58. ncbi request reprint Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Massachusetts General Hospital, Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2723-8. 2006
    ..To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in prostate-specific antigen (PSA) doubling time (PSADT) as the primary outcome variable...
  59. ncbi request reprint Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer
    Miyako Abe
    The Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Prostate Cancer 3:49-53. 2004
    ..It is possible that when used in conjunction with PSA it might prove useful in identifying patients with early-stage prostate cancer who might otherwise be missed by PSA screening alone...
  60. ncbi request reprint Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results
    Stacey B Leibowitz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Urol 170:1305. 2003
  61. doi request reprint Absence of relationship between steroid hormone levels and prostate cancer tumor grade
    David J Sher
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Urology 73:356-61; discussion 361-2. 2009
    ..To analyze the relationship between plasma testosterone and estradiol levels on prostate biopsy and radical prostatectomy Gleason scores in a cohort of patients with newly diagnosed prostate cancer...
  62. ncbi request reprint A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
    Donald S Kaufman
    Massachusetts General Hospital, Boston, MA, USA
    Urol Oncol 22:393-7. 2004
    ..Insufficient patients with poor renal function or prior therapy were accrued to reach conclusions regarding its utility in these subgroups...
  63. doi request reprint Neoadjuvant and adjuvant therapies in prostate cancer
    Fabio A B Schutz
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA
    Urol Clin North Am 37:97-104, Table of Contents. 2010
    ..This review discusses neoadjuvant and adjuvant therapies in prostate cancer, including hormonal therapy, chemotherapy, and postoperative radiotherapy...
  64. ncbi request reprint Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 96:783-6. 2005
    ....
  65. doi request reprint Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors
    M D Galsky
    Division of Hematology Oncology, Department of Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York 10029, USA
    Ann Oncol 23:1037-44. 2012
    ..The current study was designed to evaluate the effect of varying degrees of renal impairment on the safety and pharmacokinetics (PKs) of satraplatin...
  66. doi request reprint Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis
    Mei Sheng Duh
    Analysis Group, Inc, Boston, MA 02199, USA
    Curr Med Res Opin 25:2081-90. 2009
    ..This study evaluated the incremental costs associated with IV administration of selected AI therapies (bevacizumab off-label) compared to oral therapies (sunitinib or sorafenib) for the treatment of RCC...
  67. ncbi request reprint Progressive sclerosis of isolated foot metastasis of prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology and Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Urol 167:1392. 2002
  68. doi request reprint Relationship between serum adiponectin and prostate cancer grade
    David J Sher
    Harvard Radiation Oncology Program, Boston, Massachusetts 02115, USA
    Prostate 68:1592-8. 2008
    ..We evaluated the relationship between serum adiponectin and Gleason score (GS) in a prospective series of patients seen in a single institution...
  69. pmc Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer
    Mary Ellen Taplin
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA
    Clin Cancer Res 15:7099-105. 2009
    ....
  70. ncbi request reprint Male patients with diagnoses of both breast cancer and prostate cancer
    Stacey B Leibowitz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Breast J 9:208-12. 2003
    ..In addition, these men do not appear to develop prostate cancer at an earlier age or more aggressive stage than the general population...
  71. ncbi request reprint Carboplatin for stage I seminoma
    Timothy Gilligan
    J Clin Oncol 24:2971-2; author reply e32-3. 2006
  72. ncbi request reprint A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...
  73. ncbi request reprint Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer
    Phillip G Febbo
    Duke Institute for Genome Sciences and Policy, Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:152-8. 2006
    ....
  74. ncbi request reprint Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  75. ncbi request reprint The medical management of prostate cancer: a multidisciplinary team approach
    Cora N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    BJU Int 99:22-7. 2007
  76. ncbi request reprint Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 170:S3-5. 2003
  77. ncbi request reprint Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  78. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  79. ncbi request reprint Recent progress in hormonal therapy for advanced prostate cancer
    Timothy J Daskivich
    Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Opin Urol 16:173-8. 2006
    ..This review outlines the basic evidence for use of hormonal therapy while highlighting major research developments made in the past year...
  80. ncbi request reprint Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Urol Oncol 24:503-8. 2006
    ..Hyperbaric oxygen therapy can be considered a treatment option after failure of standard treatments in patients with severe radiation proctopathy...
  81. ncbi request reprint Transitional cell carcinoma of the upper uroepithelial tract
    M Dror Michaelson
    Massachusetts General Hospital, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Adv Hematol Oncol 1:102-4; discussion 105. 2003